Literature DB >> 1689143

Patterns of human tumor-infiltrating lymphocytes in 120 human cancers.

C M Balch1, L B Riley, Y J Bae, M A Salmeron, C D Platsoucas, A von Eschenbach, K Itoh.   

Abstract

Tumor-infiltrating lymphocytes from 120 samples of human cancers, including melanoma, renal cell carcinoma, breast cancer, sarcoma, and colon cancer, were examined. The percentage of lymphocytes recovered from the cancer varied widely; that of renal cell carcinoma was higher than that of breast or colon cancer (65% vs 45%), which was higher than that of melanomas or sarcomas (30% to 35%). The types of lymphocytes before and after interleukin 2 activation showed specific patterns. CD4+ helper T cells predominated in all tumors except melanomas, which had more CD8+ cytotoxic T cells. CD16+ natural killer cells were recovered in renal cell carcinoma and sarcomas. Three different cytotoxic lymphocytes were identified among interleukin 2-activated tumor-infiltrating lymphocytes: (1) CD3+ CD16- cytotoxic T lymphocytes with cytotoxicity restricted to autologous tumor cells in melanomas, (2) CD3-CD16+ natural killer cells with vigorous major histocompatibility complex-nonrestricted cytotoxicity in renal cell carcinoma, and (3) CD3+ CD16- T cells with modest levels of major histocompatibility complex-nonstricted cytotoxicity in all cancers except melanomas. Thus, there was considerable diversity of tumor-infiltrating lymphocytes among these histologically distinct tumors with respect to magnitude of lymphocyte infiltration, phenotypic expression, and functional capacity.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1689143     DOI: 10.1001/archsurg.1990.01410140078012

Source DB:  PubMed          Journal:  Arch Surg        ISSN: 0004-0010


  82 in total

1.  Selection of cytotoxic T lymphocytes against autologous human melanoma from lymph nodes with metastatic melanoma using repeated in vitro sensitization.

Authors:  S P Leong; M E Granberry; Y M Zhou; T F Wang; T M Grogan
Journal:  Clin Exp Metastasis       Date:  1991 May-Jun       Impact factor: 5.150

Review 2.  Cellular immunotherapy for malignant gliomas.

Authors:  Yi Lin; Hideho Okada
Journal:  Expert Opin Biol Ther       Date:  2016-07-29       Impact factor: 4.388

3.  HLA-DR and beta 2 microglobulin expression in medullary and atypical medullary carcinoma of the breast: histopathologically similar but biologically distinct entities.

Authors:  M Feinmesser; A Sulkes; S Morgenstern; J Sulkes; S Stern; E Okon
Journal:  J Clin Pathol       Date:  2000-04       Impact factor: 3.411

4.  Tumor-infiltrating B cell immunoglobulin variable region gene usage in invasive ductal breast carcinoma.

Authors:  Peter Simsa; Jean-Luc Teillaud; David I Stott; József Tóth; Beatrix Kotlan
Journal:  Pathol Oncol Res       Date:  2005-07-01       Impact factor: 3.201

5.  Angiogenesis and inflammation in invasive carcinoma of the breast.

Authors:  A H Lee; L C Happerfield; L G Bobrow; R R Millis
Journal:  J Clin Pathol       Date:  1997-08       Impact factor: 3.411

Review 6.  Human antibodies in cancer and autoimmune disease.

Authors:  H J Ditzel
Journal:  Immunol Res       Date:  2000       Impact factor: 2.829

7.  Alteration in interactions between tumor-infiltrating lymphocytes and tumor cells in human melanomas after chemotherapy or immunotherapy.

Authors:  K Itoh; K Hayakawa; M A Salmeron; S S Legha; J L Murray; M Talpaz; C M Balch; D R Parkinson; K Lee; A A Zukiwski
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

8.  Role of intercellular adhesion molecule-1 (ICAM-1) and lymphocyte function-associated antigen-1 (LFA-1) in peripheral blood mononuclear cell activation by human renal carcinoma cells.

Authors:  A B Hansen; C B Andersen
Journal:  Urol Res       Date:  1994

9.  Can immunotherapy by gene transfer tip the balance against colorectal cancer?

Authors:  S M Todryk; H Chong; R G Vile; H Pandha; N R Lemoine
Journal:  Gut       Date:  1998-10       Impact factor: 23.059

10.  Lymphokine production by human melanoma tumor-infiltrating lymphocytes.

Authors:  M A Salmeron; T Morita; H Seki; C D Platsoucas; K Itoh
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.